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The balanced activity of microtubule-stabilizing and -destabilizing proteins determines the extent of microtubule
dynamics, which is implicated in many cellular processes, including adhesion, migration, and morphology. Among the
destabilizing proteins, stathmin is overexpressed in different human malignancies and has been recently linked to the
regulation of cell motility. The observation that stathmin was overexpressed in human recurrent and metastatic sarcomas
prompted us to investigate stathmin contribution to tumor local invasiveness and distant dissemination. We found that
stathmin stimulated cell motility in and through the extracellular matrix (ECM) in vitro and increased the metastatic
potential of sarcoma cells in vivo. On contact with the ECM, stathmin was negatively regulated by phosphorylation.
Accordingly, a less phosphorylable stathmin point mutant impaired ECM-induced microtubule stabilization and con-
ferred a higher invasive potential, inducing a rounded cell shape coupled with amoeboid-like motility in three-
dimensional matrices. Our results indicate that stathmin plays a significant role in tumor metastasis formation, a finding
that could lead to exploitation of stathmin as a target of new antimetastatic drugs.
INTRODUCTION
Stathmin 1 (also known as OP18 [OncoProtein 18] or
metablastin) is a ubiquitously expressed cytosolic phos-
phoprotein, enriched in neuronal cells and showing a
peak of expression at the end of gestation (Koppel et al.,
1990). Like other members of its family (stathmin 2, 3, and
4), stathmin 1 (hereafter stathmin) is a microtubule (MT)-
destabilizing protein (Curmi et al., 1999), acting either by
promoting MT catastrophe (Belmont and Mitchison, 1996)
or by sequestering free -tubulin heterodimers (Howell
et al., 1999).
Experimental evidence suggests that stathmin MT-depo-
lymerizing activity is negatively regulated by phosphoryla-
tion on four serine (S) residues (S16, S25, S38, and S63).
Numerous serine-threonine kinases phosphorylate stathmin
in vitro and in living cells (Curmi et al., 1999), supporting the
hypothesis that stathmin could act as a relay for multiple
signal transduction pathways (Sobel et al., 1989). Studies
conducted in vivo in mice (Jin et al., 2004) and Drosophila
(Ozon et al., 2002; Borghese et al., 2006) and in vitro on
cultured cells (Baldassarre et al., 2005; Giampietro et al., 2005;
Ng et al., 2006; Watabe-Uchida et al., 2006) demonstrated that
stathmin plays a role in several cellular processes, including
neuritis formation and cell movement. Moreover, stathmin
is overexpressed in several types of human cancers, suggest-
ing that it could have a role in tumor progression (Melhem
et al., 1991; Curmi et al., 2000; Price et al., 2000). Recently, a
point-mutated stathmin protein (which carries a substitution at
Q18) was identified in esophageal cancer. This mutation im-
pairs stathmin phosphorylation, increases its activity, and
transforms mouse fibroblasts (Misek et al., 2002).
MT stability influences cell motility in a cell- or context-
dependent manner (Etienne-Manneville, 2004), and recent
studies found that cell contact with the extracellular matrix
(ECM) induces MT stabilization (Etienne-Manneville, 2004;
Palazzo et al., 2004), suggesting that cell movement through
ECM substrata may also be regulated by the levels and/or
activity of the MT-regulating proteins.
Together, these findings support the hypothesis that alter-
ing the MT network by deregulation of stathmin could in-
fluence cell motility, particularly in cancer cells. In the cur-
rent study, we addressed this hypothesis by investigating
the role of stathmin and its phosphorylation status in regu-
lating cell shape, growth, adhesion, and motility in vitro and
in vivo.
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MATERIALS AND METHODS
Cell Culture, Transfection, and Treatments
HT-1080 fibrosarcoma cells were grown in DMEM supplemented with 10%
fetal bovine serum (FBS; Sigma, St. Louis, MO) and transfected using Fu-
GENE 6 (Roche, Indianapolis, IN). Experiments were performed 48 h after
transfection. Stable cell clones were obtained by selecting cells in puromycin
(2 g/ml) or hygromycin (400 g/ml) for FLAG-tagged or untagged vectors,
respectively. All experiments were performed on two independent clones
derived from each construct. The expression vectors and the adenovirus used
in this study are described in the Supplementary Materials and Methods.
Proliferation, Adhesion and Migration Assays and
Time-Lapse Microscopy
Proliferation, adhesion and migration assays, and time-lapse microscopy
were performed as previously described (Baldassarre et al., 2005, Wolf et al.,
2003) and are extensively described in the Supplementary information.
Immunoblotting, Immunoprecipitation, and
Immunofluorescence
Western blot analysis was performed as previously described (Baldassarre et
al., 2005). Primary antibodies (Abs) were purchased from Sigma (actin, -
tubulin, acetylated -tubulin, polyglutamylated-tubulin, and FLAG-M1),
Santa Cruz Biotechnology (Santa Cruz, CA; -tubulin, vinculin, AKT, and
FAK), Transduction Laboratories (Lexington, KY; stathmin/metablastin),
Roche (enhanced green fluorescent protein [EGFP]), Cell Signaling (Beverly,
MA; stathmin, phospho-mitogen-activated protein kinase [pMAPK], pAKT,
pFAK, and MAPK) and Chemicon (Temecula, CA; detyrosinated Glu-tubu-
lin). Secondary HRP-conjugated antibodies were from Amersham (Piscat-
away, NJ); secondary fluorescein isothiocyanate (FITC)-, Texas red– and
Alexa Fluor 633–conjugated antibodies were from Jackson ImmunoResearch
(West Grove, PA) or Molecular Probes (Eugene, OR). For immunofluores-
cence staining, cells grown in Matrigel or Collagen I drops on coverslips for
the indicated time were fixed in PBS, 4% paraformaldehyde (PFA) at room
temperature, permeabilized in PBS, 0.2% Triton X-100, and blocked in PBS,
1% BSA, 10% normal goat serum. Incubation with primary antibodies was
performed for 3 h at room temperature (or overnight at 4°C) in PBS, 1% BSA,
and 1% normal goat serum. Nuclear staining was performed with 1 g/ml
Hoechst 33258 in PBS for 10 min at room temperature. Stained cells were
studied using a confocal laser-scanning microscope (TSP2; Leica, Deerfield,
IL) interfaced with a Leica DMIRE2 fluorescent microscope or using a Nikon
Diaphot 200 epifluorescent microscope (Melville, NY) equipped with distin-
guishing filters. Cell area and perimeter were calculated using the Leica LAS
software.
Measurement of Soluble or Polymerized Tubulin and
Tubulin Dilution Assay
Studies on tubulin polymerization were performed as reported (Baldassarre et
al., 2005) and are extensively described in the Supplementary Information.
Tumor Collection and Analysis
All primary and metastatic sarcomas were diagnosed, and samples were
collected at the CRO National Cancer Institute of Aviano, Italy. Equal
amounts of proteins extracted from 16 malignant fibrohistiocytomas and 23
leiomyosarcomas and their normal peritumoral tissues were analyzed for
stathmin and actin expression. Expression of stathmin was quantified by
densitometric scanning of the blots and normalized against actin. Immuno-
histochemical study of stathmin expression in primary and metastatic sarco-
mas was performed using a commercial anti-stathmin Ab (Cell Signaling). To
unmask the antigens from paraffin, samples were heated in the microwave for
30 min at 250 W in citrate buffer at pH 7.8.
RNA Extraction and RT-PCR
RNA from normal and neoplastic specimens from mouse organs and xeno-
grafts was extracted using the RNeasy kit (Qiagen, Chatsworth, CA). One
microgram of total RNA was retrotranscripted using MuVL Reverse Tran-
scriptase and random examers (Promega, Madison, WI); 1/10 of the obtained
cDNAs were then amplified using primers for the human stathmin sequence,
to amplify the region between amino acids 1-99 (Baldassarre et al., 2005) or
with primers for human GAPDH mRNA.
In Vivo Experiments
Nude mice were injected subcutaneously with 1  106 HT-1080 parental (n 
4), clone vector 1 (n  4), stathminWT clone A3 (n  6), stathminQ18E clones
B9 (n 4), or F7 (n 4) cells, and tumor growth was monitored for 20 d. Mice
were then killed to analyze xenografts, blood, liver, lung, and spleen for the
presence of HT-1080 cells, using RT-PCR with primers specific for the trans-
fected vectors (pFLAG for A3 and B9 or pcDNA3.1 for V1 and F7). For local
invasion, 5  105 parental (n  4) and stathminQ18E B9 (n  4) HT-1080 cells
were included in Matrigel, injected subcutaneously in nude mice, and al-
lowed to grow for 15 d. Tumors were then excised along with the surround-
ing mouse tissue and analyzed by H&E staining. For lung metastasis forma-
tion, 5  105 vector 1 (n  4) or stathminQ18E F7 (n  4) HT-1080 cells were
injected in the mouse tail vein, and lungs were analyzed 30 d later by H&E
staining. For the quantification of lung metastasis, 10 sections per lung were
analyzed. For small interfering RNA (siRNA) experiments, HT-1080 cells
were infected (MOI 300) with adenovirus (Ad)-Cont siRNA (control) or
Ad-stathmin siRNA; 3 d later, the cells (5  105) were injected into nude mice
(n  4). After 15 d, intratumoral injection of Ads was repeated, and the mice
were killed on day 30 from the initial injection.
RESULTS
Stathmin Is Deregulated in Human Sarcoma
Stathmin is overexpressed in many tumor types (e.g., leuke-
mias, breast cancer, hepatocellular carcinoma), but its con-
tribution to tumorigenesis is still poorly understood. Sarco-
mas are a class of mesenchymal tumors characterized by an
important invasive potential, responsible for their high rate
of local recurrence after surgery and distant metastasis. To
determine the role of stathmin in tumorigenesis, we evalu-
ated its expression levels, using Western blot (Figure 1) and
immunohistochemistry (Supplementary Figure 1, A–D), in a
panel of human sarcomas (16 malignant fibrohistiocytomas
and 23 leiomyosarcomas) and the normal tumor-free sur-
rounding tissue. More than 80% of the cases displayed over-
expression of stathmin in tumor specimens compared with
adjacent normal tissue (Figure 1A), with an average value
for the stathmin/actin ratio (n  10) that was twofold
higher, although this difference was not statistically signifi-
cant (p  0.187, Student’s t test; Figure 1C). When tumors
were sorted as primary or recurrent/metastatic, stathmin
expression was strongly associated with tumor relapse and
distant metastasis formation (Figure 1, B and C). Recurrent
(n  15) and metastatic sarcomas (n  14) displayed a
stathmin/actin ratio20-fold higher than that of the normal
tissue, with the difference being highly significant (p 0.001
and 0.0005, respectively). Furthermore, stathmin expression
was greatly increased (p  0.002) between primary and
recurrent/metastatic sarcomas, suggesting a role in tumor
progression. Because stathmin’s biological functions are
negatively regulated by phosphorylation, we also checked
whether stathmin overexpression was paralleled by a vari-
ation in its phosphorylation status. Focusing on normal and
sarcoma samples expressing comparable levels of total pro-
tein, we found a reduction of S16 phosphorylation in neo-
plastic samples compared with normal ones (Supplementary
Figure 1F). Similar conclusions were drawn by studying
stathmin phosphorylation in seven cases of patients with
recurrent diseases (Figure 1D). The expression of pS16, total
stathmin, and their ratios were evaluated by Western blot
and densitometric scanning of the blots. As shown in Figure
1D recurrent diseases showed a decreased pS16/stathmin
ratio (4/7 cases) or a de novo expression of total stathmin
protein (two cases). These findings support the hypothesis
that an increased stathmin expression coupled with an in-
crease in its activity could be relevant in the process of local
invasion and distant dissemination.
Stathmin Stimulates Cell Motility by Destabilizing MTs
To get deeper insight into the molecular mechanism through
which stathmin contributes to sarcoma invasiveness, we
tested the in vitro ability of stathmin to drive fibrosarcoma
cell motility. Having previously demonstrated that p27kip1
overexpression reduces ECM-dependent cell motility by in-
hibition of stathmin tubulin-sequestering activity (Baldas-
sarre et al., 2005), we better characterized the role of stathmin
in cell motility by separating its tubulin-sequestering activ-
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ity from its catastrophe-promoting one. To this purpose, we
performed an ECM-dependent motility assay utilizing stath-
minWT and two deletion mutants: stathmin1-99, retaining the
catastrophe-promoting activity, and stathmin25-149, retaining
the tubulin-sequestering activity (Howell et al., 1999). In a
human fibrosarcoma cell line (HT-1080), stathminWT over-
expression greatly enhanced cell migration through a fi-
bronectin (FN)-coated Transwell. The stathmin25-149 tubulin-
sequestering mutant induced a similar effect, whereas
stathmin1-99 was unable to do so (Figure 2A), indicating that
stathmin tubulin-sequestering activity is sufficient to stimu-
late cell motility on ECM substrata. Given the fact that
stathmin is a MT-destabilizing protein and that MT dynam-
ics play a central role in cell motility, we investigated
whether the expression of these stathmin mutants was ac-
companied by differences in the cellular MT stability. Stable
MTs, i.e., MTs with a half-life longer than 15 min (Verhey
and Gaertig, 2007), can be distinguished by a variety of
posttranslational modifications (Khawaja et al., 1988; Verhey
and Gaertig, 2007), such as acetylation, poly-glutamylation,
and detyrosination, all recognizable with specific antibodies.
We explored the amount of stable MTs in HT-1080 cells
overexpressing stathminWT or the deletion mutants after 60
min of FN adhesion, by immunofluorescence and Western
blot analysis. Expression of EGFP-stathminWT and EGFP-
stathmin25-149 proteins dramatically decreased the amount
of cellular acetylated/stable MTs (Figure 2C, left and middle
panels), whereas the EGFP-stathmin1-99 mutant has only
minor effects (right panels). Consistently, differential extrac-
tion of soluble and polymerized tubulin fractions followed
by Western blot analysis also confirmed that the stathmin1-99
mutant displayed a compromised ability to destabilize MTs
after cell adhesion to the ECM (Figure 2B).
Collectively, these data support a role for stathmin in ECM-
driven cell migration that is achieved through the MT-destabi-
lizing activity of its tubulin-sequestering domain.
Stathmin Is Phosphorylated after Cell Adhesion to
ECM Substrata
Stathmin tubulin-sequestering activity is controlled by
serine phosphorylation (Curmi et al., 1999) and by associa-
tion with several proteins, such as p27kip1 (Baldassarre et al.,
2005) or STAT3 (Ng et al., 2006). In both cases, these inter-
actions translated into an alteration of cell motility. We
Figure 1. Stathmin is overexpressed in recurrent and metastatic sarcomas. (A) Western blot analysis of stathmin expression in malignant
fibrohistiocytomas (T, left panels) or leiomyosarcomas (T, right panels) and their paired normal (N) tissues. Actin expression was used as
normalization control. (B) Western blot analysis of stathmin and actin expression in primary and recurrent/metastatic sarcomas. (C)
Statistical analysis of the stathmin/actin ratio in normal, primary, recurrent, and metastatic sarcoma samples, evaluated by densitometric
scanning of the Western blots. The median ratio for each group is reported. (D) pS16 and total stathmin expression in seven patients (Pt) with
relapsed local (R) or metastatic (M) diseases. Actin expression was used as normalization control. The ratio between pS16 and stathmin
expression, evaluated by densitometric scanning of the blots, is illustrated in the bottom graphs. P, primary sarcoma; *not detectable.
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therefore sought to investigate whether stathmin phosphor-
ylation as well was implicated in the regulation of ECM-
driven cell motility.
We first analyzed the effect of cell–ECM contact on stathmin
phosphorylation in serum-starved HT-1080 cells allowed to
adhere to FN for up to 90 min. Using three phosphospecific
antibodies recognizing pS16, pS25, and pS38 of stathmin
(Gavet et al., 1998), we observed an obvious increase of phos-
phorylated stathmin at S16 and S38 after 60 min of adhesion to
FN (Figure 3, A and B). Endogenous pS25 was not detectable,
and total stathmin levels were not affected by cell adhesion
under these conditions (Figure 3B). Time-course analysis of
cells transiently transfected with a FLAG-tagged stathmin vec-
tor confirmed that phosphorylation of S16, S38, and also S25
increased significantly after 30–90 min of adhesion, when FN
(Figure 3C) and collagen I (Coll I; Supplementary Figure 5B
and data not shown) were used as substrata.
To test whether these phosphorylations had any effect on
stathmin promigratory activity, we generated a less phospho-
rylable stathmin mutant carrying the Q18E substitution. The
stathminQ18E mutant was originally identified in human can-
cers (Misek et al., 2002) and was shown to have impaired
phosphorylation on S16 (and partially on S25 and S38), to
increase MT-depolymerization activity and to induce cell trans-
formation (Misek et al., 2002). We therefore chose to use this
more “physiological” mutant for our experiments, rather than
the “classical” serine-alanine substitution mutants. Transiently
transfected HT-1080 cells were serum starved and then ad-
hered to FN for 60 min. Under these conditions, a marked
reduction of S16 phosphorylation was observed in stathminQ18E-
expressing cells, compared with stathminWT, whereas no sig-
nificant difference in the levels of pS25 and pS38 was found
(Figure 3C). Similar results were obtained by immunofluores-
cence analysis of both endogenous and ectopically transfected
stathmin in HT-1080 cells adhered to FN (Figure 3D and Sup-
plementary Figure 2). These experiments highlight an FN-
dependent signaling pathway leading to stathmin phosphory-
lation and to the regulation of its MT-destabilizing properties.
Additional experiments will be required to identify the specific
kinase(s) participating in this pathway that leads to the ECM-
driven regulation of stathmin.
Generation and Characterization of Stathmin Stable
Cell Clones
Several stable HT-1080 cell clones overexpressing the stath-
minWT or stathminQ18E proteins were generated using either
Figure 2. Stathmin tubulin-sequestering ac-
tivity is necessary to stimulate cell motility.
(A) Migration through FN-coated FluoroBloks
of HT-1080 cells transiently transfected with
the indicated EGFP vectors. Data are ex-
pressed as the percentage of stimulation with
respect to the surrounding untransfected cells
and represent the mean (SD) of three inde-
pendent experiments, in which at least 100
transfected cells were counted. (B) Western
blot analysis of soluble (S) and polymerized
(P) fractions of tubulin in HT-1080 cells tran-
siently transfected with the indicated pFLAG-
vectors and adhered to FN for 60 min. The
expression of vinculin (loading control), -tu-
bulin, polyglutamylated-tubulin, and stath-
min is shown. (C) Confocal images of HT-1080
cells transiently transfected with the indicated
EGFP constructs (green) and stained with
phalloidin or acetylated tubulin (red). In the
bottom panels, only the acetylated tubulin
staining is shown. Yellow arrows indicate the
transfected cells.
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untagged or FLAG-tagged constructs. The complete charac-
terization in terms of proliferation, survival, and adhesion
ability of HT-1080 clone V1 (transfected with the empty
vector) and four different stathmin-expressing clones used
in this work is extensively described in the Supplementary
information. Importantly, we observed that stable stathmin
overexpression in HT-1080 cells did not significantly modify
cell proliferation, survival, or adhesion properties (Supple-
mentary Figures 3–5). Thus, we continued to focus our at-
tention on the role of stathmin in cell motility.
Stathmin Expression Enhances 3D Migration and Invasion
Parental HT-1080 and stathmin-expressing clones were
tested in different types of ECM-driven migration assays,
using FN- or Matrigel-coated Transwells or ECM inclusions.
Both stathminWT and stathminQ18E proteins promoted cell
migration (Figure 4A), invasion (Figure 4B), and evasion
(Figure 4C) through and from ECM substrata, with
stathminQ18E slightly more active than stathminWT in all
types of assays. To exclude the possibility that clonal selec-
tion could be responsible, at least partially, for the promi-
gratory behavior of stathmin-expressing cells, transiently
transfected cells were also used. One day after transfection,
cells were plated on top of or below a 1-mm-thick Matrigel
layer and allowed to invade the matrix for 3 days. The extent
of Matrigel invasion, as evaluated by confocal microscopy,
demonstrated that overexpression of EGFP-stathminWT in-
creased the ability of HT-1080 cells to invade Matrigel and
that the Q18E substitution further amplified this invasive
potential (Figure 4D). Consistently, down-regulation of en-
dogenous stathmin, by means of an adenovirus (Ad) ex-
pressing stathmin siRNA, decreased HT-1080 cell migration
through FN-coated Transwells (Figure 4E). The concomitant
expression of either EGFP-stathminWT or EGFP-stathminQ18E
proteins was able to rescue cell migratory ability (Figure 4, F
and G). On the whole, these experiments substantiate stath-
min involvement in different types of ECM-driven cell mo-
tility and the possibility that an altered stathmin phosphor-
ylation pattern, as found in human sarcoma samples (Figure
1F) or in esophageal carcinomas with the Q18E mutation
(Misek et al., 2002), increases its promigratory activity.
Stathmin Expression Does Not Enhance Fibrosarcoma Cell
Motility in Two-dimensional Assays
Altered MT dynamics have been suggested to exert an in-
hibitory role on cell motility (Liao et al., 1995; Wittmann et
al., 2004). In accordance with this hypothesis, the hyperac-
tivity of stathmin in STAT3-null fibroblasts has been consid-
ered the cause of a decreased wound closure (Ng et al., 2006).
Importantly, most of these studies were based on two-
dimensional (2D) assays, such as wound healing (reviewed
in Small et al., 2002; Rodriguez et al., 2003), which substan-
tially differ from motility in 3D matrices or in vivo (Friedl
and Brocker, 2000). We thus speculated that stathmin could
differently affect cell motility, depending on the type of
motility assayed. To verify this hypothesis, HT-1080 clones
were tested in 2D experiments. Clones expressing stath-
minWT or stathminQ18E migrated in a manner similar to that
of control cells in a wound-healing assay (Figure 5, A and B),
demonstrating that stathmin does not substantially affect
fibrosarcoma cell directional motility in 2D, as reported by
Ng et al. (2006) for normal fibroblasts. Using time-lapse
microscopy to analyze cell motility under 2D or 3D condi-
tions (Supplementary Movies 1–3), we observed that al-
though in wound healing and in 2D random motility on
plastic control and stathminQ18E-expressing cells designed
very similar trajectories, in 3D Collagen I stathminQ18E cells
covered significantly longer distances than control cells did
(Figure 5, C–E). Accordingly, stathminQ18E did not enhance
HT-single cell velocities in wound healing (Figure 3F) and in
2D random motility assays (data not shown), whereas in 3D
assays stathminQ18E cells moved significantly faster (Figure
3G).
Stathmin Expression Influences Adhesion-dependent
MT Polymerization
To determine whether increased motility of stathminQ18E-
expressing clones corresponded to molecular variations in
MT organization, we analyzed the extent of polymerized
tubulin in stathminWT and stathminQ18E HT-1080 clones, in
suspension and after 1 h of adhesion to FN. Western blot
analysis of soluble and polymerized protein fractions
showed that adhesion to ECM components leads to an im-
portant tubulin reorganization, which was in part counter-
acted when stathmin was not phosphorylable (Figure 6A),
confirming that stathminQ18E has an enhanced capability to
interfere with adhesion-dependent MT polymerization.
Moreover, after adhesion stathminQ18E induced a marked
reduction in the amount of polymerized MTs, compared
with control cells, accompanied by a reduced level of tubulin
posttranslational modifications, which are markers of MT
Figure 3. Stathmin is phosphorylated in an adhesion-dependent
manner. (A) Expression of endogenous stathmin pS16 and pS38 in
HT-1080 cells, serum starved for 8 h (S) or adherent to FN for 60 min
(FN). (B) Expression of stathmin pS16, pS25, and pS38 in HT-1080
cells, transiently transfected with pFLAG-stathmin, serum starved
for 8 h, and adhered to FN for the indicated times. Vinculin expres-
sion was used as loading control. (C) Expression of pS16, pS25, and
pS38-stathmin in HT-1080 cells, transiently transfected with FLAG-
stathminWT or FLAG-stathminQ18E, serum starved for 8 h (S), or
adhered to FN for 60 min (FN). (D) Endogenous stathmin is phos-
phorylated on S16 in an adhesion-dependent manner. S16 phos-
phorylation was detected using the phosphospecific Ab against
pS16 and a secondary FITC-conjugated anti-rabbit Ab pseudocol-
ored in green; total stathmin expression was detected using a mono-
clonal Ab against human stathmin (Transduction Laboratories) and
a secondary anti-mouse AlexaFluor 633-conjugated Ab and pseudo-
colored in red; nuclei were detected using propidium iodide and
pseudocolored in blue. In the left panel, the pS16 stathmin phos-
phorylation is specifically detected in a mitotic cell (yellow arrow).
In the right panel, the S16 phosphorylation of the endogenous
stathmin upon cell adhesion to FN for 60 min is shown. Yellow color
indicates the colocalization of green and red fluorescence.
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stability (Figure 6B). Interference with adhesion-dependent
MT polymerization by both stathminWT and stathminQ18E
was also demonstrated on transiently transfected HT-1080
cells by Western blot analysis of modified tubulin in poly-
merized and soluble cellular fractions (Figure 6C). As ex-
pected, both endogenous and transfected stathmin resided
in the soluble fraction, and stathminQ18E-expressing cells
displayed a reduced phosphorylation of S16 but not of S38
(Figure 6C). Likely for the high levels of transiently ex-
pressed stathmin proteins in these experiments, only small
differences were noticed between stathminWT and stathminQ18E
on MT polymerization (Figure 6C, fourth panel). The decrease
in MT stability induced by stathminQ18E was further confirmed
by performing the tubulin dilution assay on cells adhered to
FN for 1 h and subsequently fixed and stained with an
anti--tubulin antibody. This assay allows visualization of
only stable MTs with a half-life longer than 15 min (Khawaja
et al., 1988). Results clearly show that HT-1080 V1 cells retain
a threefold higher amount of stable MTs compared with
stathminQ18E-expressing cells (Figure 6D and data not
shown). Importantly, immunofluorescence analysis of acety-
lated (Figure 6E) and detyrosinated tubulin (data not
shown) on the same cells cultured on plastic in 2D did not
show any significant difference in the content of stable MTs,
supporting the hypothesis that stathmin affects MT poly-
merization after contact with the ECM and that stathmin
ECM-dependent phosphorylation controls this activity.
Stathmin Activity Influences HT-1080 Cell Morphology in
a 3D Matrix
Different types of cell motility in 3D assays or in vivo have
been linked to distinct molecular mechanisms controlling
cell morphology (Friedl and Wolf, 2003; Sahai and Marshall,
2003; Wolf et al., 2003). We thus examined the morphology of
HT-1080 cell clones up to 24 h after inclusion in 3D matrices
in complete or serum-reduced (1% FBS) medium. The shape
factor parameter (4A/P2, where A is the cell area and P the
cell perimeter), which varies from 0 to 1 for elongated to
more circular shapes, respectively (Peris et al., 2006), was
used to quantify cell morphology differences. Both in Coll I
after 6 h (Figure 7A) and 24 h (Figure 7B) of inclusion and in
Matrigel after 24 h (Supplementary Figure 6A), stathminQ18E-
expressing clones (i.e., B9, F7) presented a more rounded
morphology, defined by a high shape factor (Figure 7C at
24 h and Supplementary Figure 6, C and E, at 6 h; p 0.0001,
Student’s t test), compared with the elongated morphology
Figure 4. StathminWT and stathminQ18E in HT-
1080 cells confer a migratory advantage in ECM-
mediated motility assays. (A) Migration of HT-
1080 cell clones through FN-coated FluoroBloks,
expressed as a function of time. Data represent the
mean (SD) of three independent experiments,
performed in duplicate. (B) Invasion of HT-1080
cell clones through Matrigel-coated FluoroBloks,
expressed as a function of time. Data represent the
mean (SD) of three independent experiments,
performed in duplicate. (C) Matrigel evasion as-
say. HT-1080 cell clones were included in a Matri-
gel drop and allowed to evade for 5 d. A typical
image from two independent experiments per-
formed in quintuplicate is shown. The red line
indicates the border of Matrigel drops. Bar, 100
m. (D) Invasion depth expressed in micrometers,
evaluated by confocal microscopy and represent-
ing the mean (SD) of three independent experi-
ments. Only cells detached from the basal layer
were considered as invading cells. Significance
was calculated using Student’s t test. The top im-
ages show a typical computer reconstruction of
HT-1080 cells, transiently transfected with the in-
dicated EGFP vectors, invading a thick layer of
Matrigel. Cells were plated on top of the Matrigel
layer and allowed to invade in the presence of
NIH-3T3 fibroblast-conditioned medium for 3 d.
(E) Migration through FN-coated FluoroBloks of
HT-1080 cells infected with the indicated Ads, ex-
pressed as a function of time. Data represent the
mean (SD) of two independent experiments,
performed in duplicate. (F) Migration through FN-
coated FluoroBloks of HT-1080 cells infected with
Ad-stathmin siRNA at MOI 300 and then trans-
fected with the indicated EGFP vectors. Percentage
of EGFP-negative and -positive migrated cells is
reported. Data represent the mean (SD) of two
independent experiments, performed in duplicate.
(G) Western blot analysis of endogenous (stath-
min) or ectopic (EGFP) stathmin expression in HT-
1080 cells, infected with Ad-stathmin siRNA and
then transfected with the indicated EGFP vectors.
Vinculin expression was used as loading control.
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of control cells and stathminWT clones (i.e., vector clone 1
and clone A3, respectively). The absence of an effect on 3D
cell morphology of stathminWT is consistent with the re-
duced ability of low WT protein levels to interfere with
adhesion-dependent MT modification (Figure 6A). Con-
versely, when cells were simply plated on a plastic dish, no
change in cell shape was observed (by shape cell factor
calculation and immunofluorescence analysis) between con-
trol and stathminQ18E-expressing cells (Supplementary Fig-
ure 7, C and D), in accord with the data obtained with
immunofluorescence analysis (Figure 6E). The rounded
shape observed in stathminQ18E-expressing cells in 3D ma-
trices was associated with a decrease in acetylated MTs, as
demonstrated by immunofluorescence analysis (Figure 7, D
and E, p  0.0001 between control and stathmin Q18E
clones) and with a marked reduction of long-lived MTs
(Figure 7F), as demonstrated by the tubulin dilution assay.
Collectively, our results indicate that stathmin is able to
affect cell morphology in a 3D environment by acting on MT
stability.
Stathmin Expression Enhances the Metastatic Phenotype
of HT-1080 Cells
To verify whether stathmin effects on cell motility observed
in vitro could be recapitulated in vivo, nude mice were
subcutaneously injected with 1  106 parental HT-1080 cells
or HT-1080 V1 (n  8), stathminWT A3 (n  6), and
stathminQ18E B9 or F7 stable cell clones (n  8). After 20 d,
mice were killed, and the growth and metastatic ability of
each cell clone were evaluated. The analysis of the explanted
tumor masses revealed that the local tumor growth was not
markedly influenced by stathmin overexpression (Figure
8A). Distant localization of tumor cells was evaluated by
RT-PCR on RNA extracted from blood, lung, liver, or spleen,
using vector-specific primers (Figure 8, B and C). As shown
in Figure 8, B and C, tumor cells were found in distant
organs and in the blood of seven of eight mice injected with
HT-1080 stathminQ18E compared with only two of six mice
injected with HT-1080 stathminWT and none of six mice
injected with control HT-1080 cells. Stathmin effects on local
cell invasion were evaluated instead by subcutaneously in-
jecting into mice (n  4/clone) parental HT-1080 or
stathminQ18E B9 cells previously included in Matrigel. After
15 d, mice were killed and the tumor borders were exam-
ined. Although parental HT-1080 cells grew within the Ma-
trigel borders, with only few cells invading the surrounding
tissues, cells stably expressing stathminQ18E aggressively in-
vaded the surrounding host muscular tissues (Figure 8D).
We also tested the ability of stathminQ18E-expressing cells to
extravasate and localize to distant organs, in particular to
Figure 5. Stathmin expression exerts differ-
ent effects on HT-1080 cells motility in 2D and
3D assays. (A) Typical images of HT-1080 V1,
stathminWT A3, and stathminQ18E B9 clones
during a wound-healing assay, in which the
scratch was performed with a yellow tip. Bar,
100 m. (B) Quantification of the migration
distance covered by HT-1080 V1, stathminWT
A3, and stathminQ18E B9 clones, over a 24-h
period. (C–E) Orthotopically projected cell
paths of HT-1080 cell clones, V1 (empty vec-
tor), and stathminQ18E clone B9, allowed to
move toward a wound (C), randomly as
sparse cells in 2D (D) or immersed in a 3D Coll
I matrix (E), in serum-free medium. (F and G)
Statistical evaluation (Mann-Whitney U test)
of cell speed from experiments described in C
and E. Median speeds were 0.07 and 0.09 m/
min for HT-1080 V1 and stathminQ18E B9, re-
spectively, in the wound-healing assay (p 
0.7, Mann-Whitney U test) and 0.03 and 0.11
m/min for HT-1080 V1 and stathminQ18E B9,
respectively, in the 3D Coll I assay (p 
0.0001, Mann-Whitney U test).
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the lungs. To this aim, we injected HT-1080 clone V1 or
stathminQ18E clone F7 cells in the tail vein of nude mice (n
4/clone); 30 d later, we examined the mouse lungs for the
presence of metastases (Figure 8E). Pathological analysis
demonstrated that stathminQ18E-expressing cells (clone F7)
readily colonized the lungs, whereas HT-1080 V1 cells did
not. When we looked at the levels of polymerized acetylated
tubulin in explanted tumor lysates, we observed that they
correlated with the metastatic potential of sarcoma cells,
because polymerized MTs were strongly diminished in tu-
mors derived from the stathminQ18E-expressing cells (Figure
8F). The results of the in vivo experiments prove that
stathminQ18E expression strongly increases the metastatic
potential of HT-1080 cells, thus substantiating all the in vitro
data from motility evasion/invasion assays (Figure 4). To-
gether, the data reported here reinforce the hypothesis that
the invasive phenotype of stathmin-expressing cells could
be directly related to its activity on MTs and suggest that
indeed altered MT stability could also play a role in cell
invasiveness in vivo.
DISCUSSION
The present work investigates the role of the MT-destabiliz-
ing protein stathmin in sarcoma cell growth and motility
and highlights several new aspects regarding the role and
regulation of stathmin in human tumorigenesis and the
formation of metastases.
Our data point to the tubulin-sequestering activity as the
main effector of stathmin in the control of adhesion-depen-
dent MT polymerization and of cell movement. This is in
agreement with previous observations suggesting that the
catastrophe-promoting N-terminal domain plays a more
prominent role in controlling the spindle formation during
mitosis (Holmfeldt et al., 2001).
We demonstrated that stathmin is phosphorylated after
cell adhesion to ECM on at least three different serine resi-
dues, suggesting that adhesion to ECM contributes to the
regulation of stathmin activity through the modification of
its phosphorylation status. The finding that stathminQ18E,
unable to undergo S16 phosphorylation, displays a gain of
function in stimulating sarcoma cell motility suggests that
S16 phosphorylation could represent an important event in
the regulation of cell motility by stathmin. Accordingly,
recent data demonstrated that stathmin is phosphorylated
on S16 in developing neurons adherent to laminin and that
this phosphorylation is necessary for proper neuritis out-
growth (Watabe-Uchida et al., 2006). The role of adhesion-
dependent S25 and S38 phosphorylations in cell motility
remains less clear, because both these residues are readily
phosphorylated in the stathminQ18E protein. On the con-
trary, stathminQ18E did not stimulate HT-1080 cells growth.
Figure 6. Stathmin expression alters adhesion-
dependent MT stabilization in HT-1080 cells. (A)
Quantification of the polymerized fraction of
-tubulin in HT-1080 stathminWT clone D4 and
stathminQ18E clone F7, harvested in suspension
(Susp) or after adhesion to FN for 2 h (FN) and
analyzed for their soluble (S) or polymerized (P)
protein fractions. (B) Percentage of polymerized
fractions of -tubulin, acetylated-tubulin, and
detyrosinated (Glu-tub) tubulin, in HT-1080
clone V1 and stathminQ18E clones B9 and F7,
adhered to FN for 60 min. Data determined by
densitometric scanning of the blots represents
the means (SD) of three independent experi-
ments. (C) Western blot analysis of HT-1080
cells transiently transfected with pFLAG,
pFLAG-stathminWT, and pFLAG-stathminQ18E
vectors, adhered to FN for 60 min and analyzed
for their soluble (S) or polymerized (P) protein
fractions. The expressions of -tubulin, pS16-,
pS38, pan-stathmin, and vinculin are shown.
Quantification of the polymerized fraction of the
indicated cytoskeleton proteins determined by
densitometric scanning of the blots is shown in
the graphs and represents the mean (SD) of
three independent experiments. (D) Typical im-
ages of HT-1080 V1 and stathminQ18E B9 cell
clones, adhered to FN for 1 h, subjected to the
tubulin dilution assay and stained with anti--
tubulin FITC-conjugated Ab. In the graph, the
quantification of detectable MTs per cell, repre-
senting the mean of two independent experi-
ments, is reported. Data are expressed as percent
of MT number with respect to control cells; n
represents the number of analyzed cells. (E) Im-
munofluorescence analysis of acetylated-tubulin
(green) expression in HT-1080 clone V1 and
stathminQ18E clone B9 grown on plastic dishes.
Phalloidin staining of the same cells is shown in
red.
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This observation is in line with the work of Misek et al. (2002)
that showed minor effects on normal fibroblasts growth in
2D assays after expression of ectopic stathminQ18E protein.
These authors showed indeed that stathminQ18E had trans-
forming properties and increased cell growth in soft agar
assay, an effect that could not be appreciated in our model
because we used the already transformed HT-1080 cells.
Importantly, our results demonstrate that stathmin is able
to promote sarcoma cell motility through or within the ECM
in vitro and stimulate local invasion and/or metastasis for-
mation in vivo. These activities are associated with a change
in cell morphology and a decrease in stable MT content,
when cells are included in a 3D matrix or grown in vivo.
Both cytoskeletal dynamics and cell shape dictate migration
mode and efficiency in a 3D context (Friedl and Wolf, 2003;
Sahai and Marshall, 2003; Wolf et al., 2003). It has been
proposed that motility of rounded cells is characterized by
reduced cell elongation, relatively weak cell–matrix interac-
tions, and the ability of the cells to squeeze their body to
pass through the ECM fibers, using small ruffles or bleb-like
propulsive translocation. This mode of cellular migration
has been defined as “amoeboid” motility (Friedl and Wolf,
2003; Sahai and Marshall, 2003; Wolf et al., 2003). It is then
conceivable that a more dynamic and flexible MT network
(due to increased stathmin activity) could cause a switch in
the migration mode, inducing an “amoeboid”-like motility
both in vitro and in vivo. This might not only promote
tumor cell evasion from the primary site but also result in a
more rapid and distant dissemination, as proposed also by
others (Friedl and Wolf, 2003). The importance of assaying
cell flexibility in response to increased microtubule turnover
in a 3D context is underscored by the observation that
overexpression of stathminWT or stathminQ18E did not in-
crease cell motility in 2D assays (Figure 5 and Ng et al., 2006).
It is important to note that the behavior of control and
stathmin-overexpressing clones in random motility substan-
tially differs when 2D versus 3D conditions are analyzed.
This allows us to hypothesize that 3D signaling from the
matrix is specifically relevant for the enhancement of motil-
ity induced by stathmin. Our data suggest that phosphory-
lation of stathmin after cell adhesion to the ECM could
contribute at least in part to the stabilization of the MT
Figure 7. StathminQ18E expression alters HT-
1080 cell morphology in 3D matrices. (A) Hoff-
man microscopy images of HT-1080 cell clones
included in 3D Coll I and cultured in serum-
reduced (1% FBS) medium for 6 h. Bar, 30 m.
(B) Phase-contrast microscopy images of HT-
1080 cell clones immersed in 3D Coll I and
cultured in serum-reduced medium for 24 h.
Bar, 30 m. (C) Assessment of the “Shape
Factor” of HT-1080 V1 and stathminQ18E B9
clones included in 3D Coll I and cultured in
serum-reduced medium for 24 h. The Shape
Factor was calculated using the formula 4A/
P2. (D) Confocal microscopy analysis of HT-
1080 cell clones vector 1 and stathminQ18E B9
immersed in Coll I, cultured in the indicated
media (1% FBS or 10% FBS) for 24 h and
stained for acetylated tubulin (green) and F-
actin (red). Collagen fibers were visualized in
gray using the Laser 488 reflection. (E) Quan-
tification of the mean fluorescence intensity of
acetylated tubulin and F-actin, expressed as
the acetylated tubulin/F-actin ratio. Data rep-
resent the means of at least 50 cells for each
condition, analyzed by confocal microscopy
coupled with computer software analysis
(p  0.001 of V1 vs. B9 cells, using Student’s t
test). (F) Typical images of HT-1080 V1 and
stathminQ18E B9 cell clones included in 3D
Coll I and subjected to the tubulin dilution
assay and stained with anti -tubulin FITC-
conjugated Ab and AlexaFluor543-phalloidin.
Tubulin staining is shown in gray in the top
panels and in green in the bottom panels.
Phalloidin staining is in red. The graph shows
the quantification of detectable MTs per cell in
stathminQ18E-expressing cells in two indepen-
dent experiments. Data are expressed as percent
of MT number with respect to control cells; n
represents the number of analyzed cells.
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network and that impairing this pathway may result in a
switch versus an amoeboid type of motility. Our data also
confirm that the physicochemical requirements in the cell for
2D and 3D migration are distinct. A clarifying example is
given by the studies of Marshall and colleagues, on the role
of the small GTPase RhoA in cell motility. These authors
demonstrated that hyperactive RhoA decreases wound-
healing motility (Vial et al., 2003) but increases or does not
affect (depending on the cell type) cell invasion in a 3D
context (Sahai and Marshall, 2003). Moreover, recent data
suggest that increased RhoA activity at the cell periphery by
Smurf1-silencing results in decreased 2D motility, but in-
creased 3D invasive potential, in different tumor cell types
(Sahai et al., 2007). These data further confirm that the ability
of cells to move on a 2D substrata does not always parallel
the invasiveness of cancer cells. Interestingly, increasing
evidence underscores the existence of a tight relationship
between MT dynamics and small GTPase activity, because
MT stability can regulate GTPase activity (Xu et al., 2005)
and, in turn, small GTPases can affect adhesion-dependent
MT stabilization (Palazzo et al., 2004), at least in part acting
on stathmin (Watabe-Uchida et al., 2006).
It is interesting to note that stathmin down-regulation in
vivo in mice and Drosophila results in decreased motility of
proliferating neurons (Jin et al., 2004) and germ and border
cells (Ozon et al., 2002; Borghese et al., 2006), strongly sup-
porting a promigratory role for this protein. Moreover, the
fact that the MT-stabilizing protein MAP2 is down-regulated
in metastatic melanomas with respect to primary tumors
(Soltani et al., 2005)—whereas stathmin is overexpressed in
metastatic versus clinically localized prostate carcinomas
(Varambally et al., 2005), invasive recurrent hepatocarcino-
mas (Yuan et al., 2006), advanced mammary carcinomas
(Van’t Veer et al., 2002), and recurrent/metastatic sarcomas
(our work)—suggests that decreased MT stability could be a
general feature in the process of metastasis formation. Our
findings indicate that increased stathmin expression and/or
activity stimulates sarcoma cell migration in vitro, enhances
local and distant dissemination in mice, and correlates with
sarcoma recurrence and metastasis formation in human dis-
ease. Altogether, these data strongly point to stathmin as a
potential prognostic factor and a promising target for bio-
logical therapies in refractory diseases, at least in soft tissue
sarcomas.
ACKNOWLEDGMENTS
We are grateful to Dr. Andre´ Sobel (INSERM, Paris, France) for providing the
anti-phospho-stathmin antibodies and to Dr. Greg G. Gundersen (Columbia
University, New York, NY) for providing the anti-Glu-Tubulin Ab. We thank
Figure 8. Stathmin expression enhances HT-
1080 cell invasion and metastasis formation in
vivo. (A) In vivo growth of parental and stably
transfected HT-1080 cell clones subcutane-
ously injected in nude mice. (B) RT-PCR anal-
ysis of RNA of tissues explanted from mice
injected with HT-1080 V1 and stathminQ18E B9
cell clones. Amplification was performed us-
ing primers designed on the transfected vec-
tors. Amplification of actin was used as a con-
trol. (C) RT-PCR analysis of RNA extracted
from blood derived from mice subcutaneously
injected with HT-1080 cell clones, using prim-
ers designed on the transfected vectors. Am-
plification of actin was used as a control. (D)
Local invasion of HT-1080 cells included in
Matrigel and then injected subcutaneously
into nude mice (n  4). Fifteen days after the
injection, tumors were explanted and ana-
lyzed by H&E staining. Typical images ac-
quired at 10 (left panels) or 40 (right pan-
els) are shown. (E) Lung metastasis formation
in mice injected in the tail vein with HT-1080
V1 or stathminQ18E F7 cell clones and analyzed
by H&E staining 30 d after the injection. The
quantification of lung metastases in mice in-
jected with HT-1080 V1 or stathminQ18E F7 cell
clones is shown in the graph. (F) Analysis of
soluble and polymerized acetylated tubulin
content in tumors derived from the indicated
HT-1080 cell clones. Percentage of polymer-
ized fractions (% Pol.) of acetylated tubulin
was calculated as described above.
B. Belletti et al.
Molecular Biology of the Cell2012
Bruna Wassermann and Margit Ott for excellent technical support. This work
was supported by grants from Associazione Italiana Ricerca sul Cancro
(AIRC) and partially from Association for International Cancer Research
(AICR) and Ministero della Salute to G.B. F.L. is recipient of an AIRC fellow-
ship.
REFERENCES
Baldassarre, G., Belletti, B., Nicoloso, M. S., Schiappacassi, M., Vecchione, A.,
Spessotto, P., Morrione, A., Canzonieri, V., and Colombatti, A. (2005).
p27(Kip1)-stathmin interaction influences sarcoma cell migration and inva-
sion. Cancer Cell 7, 51–63.
Belmont, L. D., and Mitchison, T. J. (1996). Identification of a protein that
interacts with tubulin dimers and increases the catastrophe rate of microtu-
bules. Cell 84, 623–631.
Borghese, L., Fletcher, G., Mathieu, J., Atzberger, A., Eades, W. C., Cagan,
R. L., and Rorth, P. (2006). Systematic analysis of the transcriptional switch
inducing migration of border cells. Dev. Cell 10, 497–508.
Curmi, P. A., Gavet, O., Charbaut, E., Ozon, S., Lachkar-Colmerauer, S.,
Manceau, V., Siavoshian, S., Maucuer, A., and Sobel, A. (1999). Stathmin and
its phosphoprotein family: general properties, biochemical and functional
interaction with tubulin. Cell Struct. Funct. 24, 345–357.
Curmi, P. A., Nogues, C., Lachkar, S., Carelle, N., Gonthier, M. P., Sobel, A.,
Lidereau, R., and Bieche, I. (2000). Overexpression of stathmin in breast
carcinomas points out to highly proliferative tumours. Br. J. Cancer 82,
142–150.
Etienne-Manneville, S. (2004). Actin and microtubules in cell motility: which
one is in control? Traffic 5, 470–477.
Friedl, P., and Brocker, E. B. (2000). The biology of cell locomotion within
three-dimensional extracellular matrix. Cell. Mol. Life Sci. 57, 41–64.
Friedl, P., and Wolf, K. (2003). Tumour-cell invasion and migration: diversity
and escape mechanisms. Nat. Rev. Cancer 3, 362–374.
Gavet, O., Ozon, S., Manceau, V., Lawler, S., Curmi, P., and Sobel, A. (1998).
The stathmin phosphoprotein family: intracellular localization and effects on
the microtubule network. J. Cell Sci. 111(Pt 22), 3333–3346.
Giampietro, C., Luzzati, F., Gambarotta, G., Giacobini, P., Boda, E., Fasolo, A.,
and Perroteau, I. (2005). Stathmin expression modulates migratory properties
of GN-11 neurons in vitro. Endocrinology 146, 1825–1834.
Holmfeldt, P., Larsson, N., Segerman, B., Howell, B., Morabito, J., Cassimeris,
L., and Gullberg, M. (2001). The catastrophe-promoting activity of ectopic
Op18/stathmin is required for disruption of mitotic spindles but not inter-
phase microtubules. Mol. Biol. Cell 12, 73–83.
Howell, B., Larsson, N., Gullberg, M., and Cassimeris, L. (1999). Dissociation
of tubulin-sequestering and microtubules catastrophe-promoting activities of
Oncoprotein 18/stathmin. Mol. Biol. Cell 10, 105–118.
Jin, K. et al. (2004). Proteomic and immunochemical characterization of a role
for stathmin in adult neurogenesis. FASEB J. 18, 287–299.
Khawaja, S., Gundersen, G. G., and Bulinski, J. C. (1988). Enhanced stability of
microtubules enriched in detyrosinated tubulin is not a direct function of
detyrosination level. J. Cell Biol. 106, 141–149.
Koppel, J., Boutterin, M. C,. Doye, V., Peyro-Saint-Paul, H., and Sobel, A.
(1990). Developmental tissue expression and phylogenetic conservation of
stathmin, a phosphoprotein associated with cell regulations. J. Biol. Chem.
265, 3703–3707.
Liao, G., Nagasaki, T., and Gundersen, G. G. (1995). Low concentrations of
nocodazole interfere with fibroblast locomotion without significantly affecting
microtubule level: implications for the role of dynamic microtubules in cell
locomotion. J. Cell Sci. 108, 3473–3483.
Melhem, R. F., Zhu, X. X., Hailat, N., Strahler, J. R., and Hanash, S. M. (1991).
Characterization of the gene for a proliferation-related phosphoprotein (on-
coprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 266,
17747–17753.
Misek, D. E., Chang, C. L., Kuick, R., Hinderer, R., Giordano, T. J., Beer, D. G.,
and Hanash, S. M. (2002). Transforming properties of a Q183E mutation of
the microtubule regulator Op18. Cancer Cell 2, 217–228.
Ng, D.C.H., Lin, B. H., Lim, C. P., Huang, G., Zhang, T., Poli, V., and Cao, X.
(2006). Stat3 regulates microtubules by antagonizing the depolymerization
activity of stathmin. J. Cell Biol. 172, 245–257.
Ozon, S., Guichet, A., Gavet, O., Roth, S., and Sobel, A. (2002). Drosophila
stathmin: a microtubule-destabilizing factor involved in nervous system for-
mation. Mol. Biol. Cell 13, 698–710.
Palazzo, A. F., Eng, C. H., Schlaepfer, D. D., Marcantonio, E. E., Gundersen,
G. G. (2004). Localized stabilization of microtubules by integrin- and FAK-
facilitated Rho signaling. Science 303, 836–839.
Peris, L. et al. (2006). Tubulin tyrosination is a major factor affecting the
recruitment of CAP-Gly proteins at microtubule plus ends. J. Cell Biol. 174,
839–849.
Price, D. K., Ball, J. R., Bahrani-Mostafavi, Z., Vachris, J. C., Kaufman, J. S.,
Naumann, R. W., Higgins, R. V., and Hall, J. B. (2000). The phosphoprotein
Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest.
18, 722–730.
Rodriguez, O. C., Schaefer, A. W., Mandato, C. A., Forscher, P., Bement,
W. M., and Waterman-Storer, C. M. (2003). Conserved microtubule-actin
interactions in cell movement and morphogenesis. Nat. Cell Biol. 5, 599–609.
Sahai, E., and Marshall, C. J. (2003). Differing modes of tumour cell invasion
have distinct requirements for Rho/ROCK signalling and extracellular pro-
teolysis. Nat. Cell. Biol. 5, 711–719.
Sahai, E., Garcia-Medina, R., Pouyssegur, J., and Vial, E. (2007). Smurf1
regulates tumor cell plasticity and motility through degradation of RhoA
leading to localized inhibition of contractility J. Cell Biol. 176, 35–42.
Small, J. V., Geiger, B., Kaverina, I., and Bershadsky, A. (2002). How do
microtubules guide migrating cells? Nat. Rev. Mol. Cell Biol. 3, 957–964.
Sobel, A., Boutterin, M. C., Beretta, L., Chneiweiss, H., Doye, V., and Peyro-
Saint-Paul, H. (1989). Intracellular substrates for extracellular signaling. Char-
acterization of a ubiquitous, neuron-enriched phosphoprotein (stathmin).
J. Biol. Chem. 264, 3765–3772.
Soltani, M. H., Pichardo, R., Song, Z., Sangha, N., Camacho, F., Satyamoorthy,
K., Sangueza, O. P., and Setaluri, V. (2005). Microtubule-associated protein 2,
a marker of neuronal differentiation, induces mitotic defects, inhibits growth
of melanoma cells, and predicts metastatic potential of cutaneous melanoma.
Am. J. Pathol. 166, 1841–1850.
Van ’t Veer, L. J. et al. (2002). Gene expression profiling predicts clinical
outcome of breast cancer. Nature 415, 530–536.
Varambally, S. et al. (2005). Integrative genomic and proteomic analysis of
prostate cancer reveals signatures of metastatic progression. Cancer Cell 8,
393–406.
Vial, E., Sahai, E., and Marshall, C. J. (2003). ERK-MAPK signaling coordi-
nately regulates Rac1 and RhoA for tumor cell motility. Cancer Cell 4, 67–79.
Watabe-Uchida, M., John, K. A., Janas, J. A., Newey, S. E., and Van Aelst, L.
(2006). The Rac activator DOCK7 regulates neuronal polarity through local
phosphorylation of stathmin/Op18. Neuron 51, 727–739.
Verhey, K. J., and Gaertig, J. (2007). The tubulin code. Cell Cycle 6, 2152–2160.
Wittmann, T., Bokoch, G. M., and Waterman-Storer, C. M. (2004). Regulation
of microtubule destabilizing activity of Op18/stathmin downstream of Rac1.
J. Biol. Chem. 279, 6196–6203.
Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina,
E. I., Strongin, A. Y., Brocker, E. B., and Friedl, P. (2003). Compensation
mechanism in tumor cell migration: mesenchymal-amoeboid transition after
blocking of pericellular proteolysis. J. Cell Biol. 160, 267–277.
Yuan, R. H., Jeng, Y. M., Chen, H. L., Lai, P. L., Pan, H. W., Hsieh, F. J., Lin,
C. Y., Lee, P. H., and Hsu, H. C. (2006). Stathmin overexpression cooperates
with p53 mutation and osteopontin overexpression, and is associated with
tumour progression, early recurrence, and poor prognosis in hepatocellular
carcinoma. J. Pathol. 209, 549–558.
Xu, J., Wang, F., Van Keymeulen, A., Rentel, M., and Bourne, H. R. (2005).
Neutrophil microtubules suppress polarity and enhance directional migra-
tion. Proc. Natl. Acad. Sci. USA 102, 6884–6889.
Stathmin in Cell Motility and Invasion
Vol. 19, May 2008 2013
